Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs
- PMID: 8055145
- DOI: 10.1111/j.1540-8167.1994.tb01179.x
Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs
Abstract
The mechanism of torsades de pointes as a proarrhythmic response to antiarrhythmic drugs is not clear. We hypothesized that the difference in the corrected QT interval (QTc, Bazett's formula) with varying autonomic tone and heart rate during 24-hour ambulatory ECG would help identify patients at risk. Ten patients with antiarrhythmic drug-induced torsades de pointes were compared with 28 controls. The QTc at maximal and minimal heart rate during antiarrhythmic drug-free ambulatory ECGs were measured. The mean QTc at minimal heart rates for patients was 0.413 +/- 0.102 seconds and 0.420 +/- 0.072 seconds and for controls (P = 0.715). The mean QTc at maximal heart rates for patients was 0.555 +/- 0.022 seconds and for controls was 0.439 +/- 0.011 seconds (P = 0.001). Mean QTc between minimal and maximal heart rates were significantly different for patients (P = 0.015) but were not for controls (P = 0.151). Using an arbitrary QTc difference cutoff of 0.075 seconds, this approach identified patients at risk for antiarrhythmic drug-induced torsades de pointes with a sensitivity of 70% (7 of 10) and a specificity of 89% (P < or = 0.003 by Chi-square analysis with Yates' correction). In conclusion, patients with antiarrhythmic drug-induced torsades de pointes had a greater rise in QTc from minimal to maximal heart rate during ambulatory ECG than controls. Further larger prospective trials will be required to establish the value of this approach to identify patients at risk for this type of proarrhythmia.
Similar articles
-
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.JAMA. 1993 Dec 1;270(21):2590-7. doi: 10.1001/jama.270.21.2590. JAMA. 1993. PMID: 8230644
-
Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.Eur Heart J. 1995 May;16(5):667-73. doi: 10.1093/oxfordjournals.eurheartj.a060971. Eur Heart J. 1995. PMID: 7588899
-
Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.J Cardiovasc Pharmacol. 1997 Mar;29(3):373-81. doi: 10.1097/00005344-199703000-00011. J Cardiovasc Pharmacol. 1997. PMID: 9125676
-
Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.Am J Cardiol. 1993 Aug 26;72(6):10B-13B. doi: 10.1016/0002-9149(93)90033-9. Am J Cardiol. 1993. PMID: 8256748 Review.
-
Antiarrhythmic drugs and torsade de pointes.Eur Heart J. 1993 Nov;14 Suppl H:88-92. doi: 10.1093/eurheartj/14.suppl_h.88. Eur Heart J. 1993. PMID: 8293758 Review.
Cited by
-
Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.Antimicrob Agents Chemother. 2010 Jun;54(6):2448-54. doi: 10.1128/AAC.01447-09. Epub 2010 Mar 29. Antimicrob Agents Chemother. 2010. PMID: 20350942 Free PMC article. Clinical Trial.
-
Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.Pharm Res. 2016 Jan;33(1):40-51. doi: 10.1007/s11095-015-1760-9. Epub 2015 Nov 9. Pharm Res. 2016. PMID: 26553352 Free PMC article.
-
Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: Findings from the Penn Atrial Fibrillation Free study.Heart Rhythm. 2016 Feb;13(2):527-35. doi: 10.1016/j.hrthm.2015.11.008. Epub 2015 Nov 10. Heart Rhythm. 2016. PMID: 26552754 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources